DUBLIN–(BUSINESS WIRE)–The “Oncology Drugs Market Research Report by Indication (Bladder Cancer, Breast Cancer, and Cervical Cancer), Drug Class Type, Distribution, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.
The Global Oncology Drugs Market size was estimated at USD 114.02 billion in 2021, USD 122.71 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.80% to reach USD 178.95 billion by 2027.
In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward.
The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.
It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others.
Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate.
The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
- AbbVie Inc.
- Ability Pharma
- Acadia Pharmaceuticals Inc.
- Aegerion Pharmaceuticals Inc.
- Amgen Inc.
- ARIAD Pharmaceuticals, Inc.
- Aslan Pharmaceuticals Ltd.,
- Aspen Pharmacare Holdings Limited
- Astellas Pharma Inc.
- AstraZeneca PLC
- Athenex, Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc
- GlaxoSmithKline PLC
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in incidence of cancer across the globe
5.1.1.2. Surge in global geriatric population
5.1.1.3. Increase in government expenditures on healthcare
5.1.1.4. Elevated development of Biosimilar in Oncology arena
5.1.2. Restraints
5.1.2.1. Adverse effects associated with the use of cancer drugs
5.1.3. Opportunities
5.1.3.1. Untapped emerging economies
5.1.3.2. Increase in number of pipeline drugs
5.1.4. Challenges
5.1.4.1. High cost of the drug
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Oncology Drugs Market, by Indication
6.1. Introduction
6.2. Bladder Cancer
6.3. Breast Cancer
6.4. Cervical Cancer
6.5. Colorectal Cancer
6.6. Esophagus Cancer
6.7. Kidney Cancer
6.8. Liver Cancer
6.9. Lung Cancer
6.10. Prostate Cancer
6.11. Stomach Cancer
7. Oncology Drugs Market, by Drug Class Type
7.1. Introduction
7.2. Chemotherapy
7.3. Hormonal Therapy
7.4. Immunotherapy
7.5. Targeted Therapy
8. Oncology Drugs Market, by Distribution
8.1. Introduction
8.2. Hospitals Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Oncology Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Oncology Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Oncology Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
13. Company Usability Profiles
For more information about this report visit https://www.researchandmarkets.com/reports/4896719/oncology-drugs-market-research-report-by?utm_source=BW&utm_medium=PressRelease&utm_code=gg84kx&utm_campaign=1700006+-+Global+Oncology+Drugs+Market+Research+Report+2022-2027%3a+Untapped+Emerging+Economies+%26+Increase+in+Number+of+Pipeline+Drugs&utm_exec=chdo54prd
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900